forty-two patients with multiple myeloma were allocated to two groups to receive either polychemotherapy with vincristine , melphalan , cyclophosphamide and prednisolone , or recombinant interferon-alpha 2c monotherapy .
C0026764
multiple myeloma
C0025241
melphalan